| Identification | Back Directory | [Name]
BCTC | [CAS]
393514-24-4 | [Synonyms]
BCTC
N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
1-Piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-
4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-diMethylethyl)phenyl]-1-piperazinecarboxaMide (BCTC) | [Molecular Formula]
C20H25ClN4O | [MDL Number]
MFCD08690556 | [MOL File]
393514-24-4.mol | [Molecular Weight]
372.89 |
| Chemical Properties | Back Directory | [Melting point ]
150-152℃ | [Boiling point ]
561.6±50.0 °C(Predicted) | [density ]
1.229±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO: >10mg/mL | [form ]
powder | [pka]
13.95±0.70(Predicted) | [color ]
white to beige | [Sensitive ]
Light Sensitive | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stord at -20°C for up to 2 months. | [InChI]
InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26) | [InChIKey]
ROGUAPYLUCHQGK-UHFFFAOYSA-N | [SMILES]
N1(C(NC2=CC=C(C(C)(C)C)C=C2)=O)CCN(C2=NC=CC=C2Cl)CC1 |
| Hazard Information | Back Directory | [Description]
BCTC (393514-24-4) is a vanilloid receptor I (TRPV1) blocker, IC50 = 35 nM for capsaicin-induced and 6 nM for acid-induced TRPV1 activation. Displays analgesic activity in rat models of neuropathic pain. BCTC is orally active and cell permeable. | [Uses]
BCTC is a antagonists of TRPA1 and TRPV1, a non-selective cation channel gated by noxious heat, vanilloids and extracellular protons. BCTC inhibits both capsaicin and proton activation. | [Definition]
ChEBI: 1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- is a member of piperazines and a member of pyridines. | [in vivo]
BCTC (1-30 mg/kg; Oral gavage; Single dose) can inhibit inflammatory and neuropathic heat pain and mechanical hyperalgesia in Sprague-Dawley rats by targeting VR1, which has analgesic effect[2].
BCTC (10-100 mg/kg; Oral gavage, Twice daily for 4 weeks) improves the insulin resistance and systemic glucose and lipid metabolism, and increase insulin secretion in diabetic ob/ob mice[5].
| Animal Model: | Capsaicin-induced Sprague-Dawley rats model[2] | | Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Oral gavage (p.o.), Single dose. Before capsaicin (HY-10448) treatment (30 μg; intraplantar injection; Single dose) | | Result: | Inhibited capsaicin-mediated thermal hyperalgesia in a dose-dependent manner. |
| Animal Model: | Freund’s complete adjuvant (FCA) Sprague-Dawley rats model[2] | | Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Oral gavage (p.o.), Single dose. After 100 % FAC treatment (50 μL; intraplantar injection; Single dose) | | Result: | Significantly reduced FAC-induced inflammation-related thermal pain and mechanical hyperalgesia, and extended the inhibitory effect of mechanical hyperalgesia to 6 h at high doses (10 mg/kg, 30 mg/kg). |
| Animal Model: | Partial sciatic nerve ligation Sprague-Dawley rats model[2] | | Dosage: | 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg | | Administration: | Oral gavage (p.o.), Single dose. After partial sciatic nerve ligation. | | Result: | Reduced post-operative abnormal tactile pain and mechanical hyperalgesia in a dose-dependent manner. |
| Animal Model: | Particularly strong insulin resistance and hyperinsulinemia ob/ob mice model[5] | | Dosage: | 10 mg/kg, 30 mg/kg, 100 mg/kg | | Administration: | Oral gavage (p.o.); Twice daily for 4 weeks | | Result: | Reduced plasma triglyceride and glucose area under the curve (AUC) level.
Decreased calcitonin gene-related peptide (CGRP) levels in a dose-dependent manner.
|
| [storage]
Store at RT | [References]
1) Valenzano et al. (2003), N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties; J. Pharmacol. Exp. Ther., 306 377
2) Pomonis et al. (2003), N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain; J. Pharmacol. Exp. Ther., 306 387 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|